Reaction
Refractory Cancer reporting signals
As of the last recalculation, Refractory Cancer appears in 214 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is POLATUZUMAB VEDOTIN (PRR 184.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Polatuzumab Vedotin | 17 | 184.0 | 184.3 |
| Axicabtagene Ciloleucel | 17 | 181.9 | 182.2 |
| Gemcitabine | 51 | 165.0 | 165.2 |
| Gemcitabine Hydrochloride | 56 | 138.7 | 138.8 |
| Bendamustine Hcl | 17 | 115.7 | 115.9 |
| Obinutuzumab | 17 | 109.1 | 109.2 |
| Etoposide | 50 | 86.0 | 86.1 |
| Cisplatin | 50 | 80.9 | 81.0 |
| Doxorubicin | 55 | 80.5 | 80.5 |
| Ifosfamide | 14 | 67.7 | 67.8 |
| Carfilzomib | 18 | 67.5 | 67.5 |
| Doxorubicin Hydrochloride | 18 | 58.4 | 58.5 |
| Bleomycin Sulfate | 6 | 58.1 | 58.1 |
| Thiotepa | 5 | 52.1 | 52.1 |
| Thalidomide | 18 | 52.0 | 52.0 |
| Venetoclax | 26 | 46.6 | 46.6 |
| Blinatumomab | 4 | 38.0 | 38.0 |
| Daratumumab | 14 | 36.4 | 36.4 |